GSK plc (GSK)
NYSE: GSK · Real-Time Price · USD
36.35
-1.02 (-2.73%)
At close: May 13, 2025, 4:00 PM
36.77
+0.42 (1.16%)
Pre-market: May 14, 2025, 9:11 AM EDT

Revenue by Product

Fiscal year is January - December.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2012 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2012 - 2019
HIV
7.09B
Log In
Log In
Log In
Log In
Upgrade
HIV Growth
10.01%
Log In
Log In
Log In
Log In
Upgrade
Meningitis
1.44B
Log In
Log In
Log In
Log In
Upgrade
Meningitis Growth
14.05%
Log In
Log In
Log In
Log In
Upgrade
Influenza
408.00M
Log In
Log In
Log In
Log In
Upgrade
Influenza Growth
-19.05%
Log In
Log In
Log In
Log In
Upgrade
Established Vaccines
3.34B
Log In
Log In
Log In
Log In
Upgrade
Established Vaccines Growth
2.24%
Log In
Log In
Log In
Log In
Upgrade
Vaccines
9.14B
Log In
Log In
Log In
Log In
Upgrade
Vaccines Growth
-7.36%
Log In
Log In
Log In
Log In
Upgrade
Shingles
3.36B
Log In
Log In
Log In
Log In
Upgrade
Shingles Growth
-2.38%
Log In
Log In
Log In
Log In
Upgrade
Oncology
1.41B
Log In
Log In
Log In
Log In
Upgrade
Oncology Growth
92.89%
Log In
Log In
Log In
Log In
Upgrade
Immuno-Inflammation, Respiratory and Other
3.30B
Log In
Log In
Log In
Log In
Upgrade
Immuno-Inflammation, Respiratory and Other Growth
9.06%
Log In
Log In
Log In
Log In
Upgrade
Specialty Medicines
11.81B
Log In
Log In
Log In
Log In
Upgrade
Specialty Medicines Growth
15.29%
Log In
Log In
Log In
Log In
Upgrade
Respiratory
7.21B
Log In
Log In
Log In
Log In
Upgrade
Respiratory Growth
5.68%
Log In
Log In
Log In
Log In
Upgrade
Other General Medicines
3.22B
Log In
Log In
Log In
Log In
Upgrade
Other General Medicines Growth
-5.30%
Log In
Log In
Log In
Log In
Upgrade
General Medicines
10.43B
Log In
Log In
Log In
Log In
Upgrade
General Medicines Growth
2.04%
Log In
Log In
Log In
Log In
Upgrade
Total Commerical Operations
31.38B
Log In
Log In
Log In
Log In
Upgrade
Total Commerical Operations Growth
3.46%
Log In
Log In
Log In
Log In
Upgrade
Total Consumer Healthcare
-
Log In
Log In
Log In
Log In
Upgrade
Pandemic
-
Log In
Log In
Log In
Log In
Upgrade
Pandemic Growth
-
Log In
Log In
Log In
Log In
Upgrade
Pandemic Vaccines
-
Log In
Log In
Log In
Log In
Upgrade
Pandemic Vaccines Growth
-
Log In
Log In
Log In
Log In
Upgrade

EBIT by Product

Fiscal year is January - December.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2012 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2012 - 2019
Commercial Operations Segment Profit
15.34B
Log In
Log In
Log In
Log In
Upgrade
Commercial Operations Segment Profit Growth
4.63%
Log In
Log In
Log In
Log In
Upgrade
Research & Development Segment Profit
-5.85B
Log In
Log In
Log In
Log In
Upgrade
Research & Development Segment Profit Growth
4.24%
Log In
Log In
Log In
Log In
Upgrade
Consumer Healthcare Segment Profit
-
Log In
Log In
Log In
Log In
Upgrade

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2012 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2012 - 2019
US Revenue
16.38B
Log In
Log In
Log In
Log In
Upgrade
US Revenue Growth
3.57%
Log In
Log In
Log In
Log In
Upgrade
Europe
6.67B
Log In
Log In
Log In
Log In
Upgrade
Europe Growth
1.55%
Log In
Log In
Log In
Log In
Upgrade
International
8.33B
Log In
Log In
Log In
Log In
Upgrade
International Growth
4.81%
Log In
Log In
Log In
Log In
Upgrade